Vis enkel innførsel

dc.contributor.authorStrand, Elinen_US
dc.contributor.authorPedersen, Eva Ringdalen_US
dc.contributor.authorSvingen, Gard Frodahl Tveitevågen_US
dc.contributor.authorOlsen, Thomasen_US
dc.contributor.authorBjørndal, Bodilen_US
dc.contributor.authorKarlsson, Thereseen_US
dc.contributor.authorDierkes, Juttaen_US
dc.contributor.authorNjølstad, Pål Rasmusen_US
dc.contributor.authorMellgren, Gunnaren_US
dc.contributor.authorTell, Grethe S.en_US
dc.contributor.authorBerge, Rolf Kristianen_US
dc.contributor.authorSvardal, Asbjørn M.en_US
dc.contributor.authorNygård, Ottaren_US
dc.PublishedStrand E, Pedersen ER, Svingen GFTS, Olsen T, Bjørndal B, Karlsson T, Dierkes J, Njølstad PR, Mellgren G, Tell GST, Berge RK, Svardal AM, Nygård O. Serum Acylcarnitines and Risk of Cardiovascular Death and Acute Myocardial Infarction in Patients With Stable Angina Pectoris. Journal of the American Heart Association. 2017;6(2):e003620eng
dc.description.abstractBackground: Excess levels of serum acylcarnitines, which are intermediate products in metabolism, have been observed in metabolic diseases such as type 2 diabetes mellitus. However, it is not known whether acylcarnitines may prospectively predict risk of cardiovascular death or acute myocardial infarction in patients with stable angina pectoris. Methods and Results: This study included 4164 patients (median age, 62 years; 72% men). Baseline serum acetyl‐, octanoyl‐, palmitoyl‐, propionyl‐, and (iso)valerylcarnitine were measured using liquid chromatography/tandem mass spectrometry. Hazard ratios (HRs) and 95% CIs for quartile 4 versus quartile 1 are reported. The multivariable model included age, sex, body mass index, fasting status, current smoking, diabetes mellitus, apolipoprotein A1, apolipoprotein B, creatinine, left ventricular ejection fraction, extent of coronary artery disease, study center, and intervention with folic acid or vitamin B6. During median 10.2 years of follow‐up, 10.0% of the patients died of cardiovascular disease and 12.8% suffered a fatal or nonfatal acute myocardial infarction. Higher levels of the even‐chained acetyl‐, octanoyl‐, and palmitoyl‐carnitines were significantly associated with elevated risk of cardiovascular death, also after multivariable adjustments (HR [95% CI]: 1.52 [1.12, 2.06]; P=0.007; 1.73 [1.23, 2.44]; P=0.002; and 1.61 [1.18, 2.21]; P=0.003, respectively), whereas their associations with acute myocardial infarction were less consistent. Conclusions: Among patients with suspected stable angina pectoris, elevated serum even‐chained acylcarnitines were associated with increased risk of cardiovascular death and, to a lesser degree with acute myocardial infarction, independent of traditional risk factors.en_US
dc.rightsAttribution CC BY-NC-NDeng
dc.subjectangina pectoriseng
dc.subjectcardiovascular outcomeseng
dc.titleSerum Acylcarnitines and Risk of Cardiovascular Death and Acute Myocardial Infarction in Patients With Stable Angina Pectorisen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2017 The Author(s)
dc.source.journalJournal of the American Heart Association

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY-NC-ND
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY-NC-ND